Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cardiovascular Metabolic Disorders

Cerenis closes C round at €50M

This article was originally published in Scrip

Executive Summary

Cerenis Therapeutics has, as expected, has closed its series C round with an additional €10 million from IXO Private Equity, IRDI and an undisclosed private investor. The latest tranche takes the total funds raised in the round to €50 million and the total amount raised historically to €117 million. Cerenis completed a first closing of the round at €40 million in July, half of which came from new investor FSI, with the balance coming from existing investors Alta Partners, DAIWA Corporate Investment, EDF Ventures, HealthCap, OrbiMed, Sofinnova Partners and TVM Capital (scripintelligence.com 26 July 2010).

Table

View full table

Topics

Related Companies

Tags:
Cardiovascular Metabolic Disorders
Latest Headlines

‘It’s Not About Me’ – AstraZeneca’s Soriot Says His Pay Rise Will Help European Pharma

Executives On The Move: Three New CEOs Among This Week's Changes

Sanofi To Pursue Smart M&A Pacts And Stick With Early-Stage Oncology R&D

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

See All
UsernamePublicRestriction

Register

SC010545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By